Navigation Links
Ansun BioPharma Announces Potent in-vitro DAS181 Activity against Respiratory Syncytial Virus at 5th Congress of Virology
Date:12/8/2015

SAN DIEGO, Dec. 8, 2015 /PRNewswire/ -- Ansun BioPharma announced preliminary data suggesting in-vitro activity of DAS181 against Respiratory Syncytial Virus (RSV), a virus which causes significant morbidity and mortality in patients. The data was presented at the 5th Congress of Virology in Atlanta, Georgia in a keynote address by Ronald Moss, MD, CEO of Ansun. The in-vitro inhibition against the virus was observed to be more potent than Ribavarin, the current treatment for RSV. "This is very important data as RSV is a common respiratory pathogen and additional treatments are needed," noted Dr. Moss. "As DAS181 is currently in the clinic being studied for the treatment of other respiratory viruses, clinical trials are warranted to test the efficacy of this drug against RSV infection as well," commented Dr. Moss.

About Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses.  DAS181 has two indications in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of severe parainfluenza infection in immunocompromised patients. ParaDaseTM has received Fast Track Designation by the U.S. FDA. Preclinical data suggests that DAS181 may have additional activity against other respiratory viruses. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.

 


'/>"/>
SOURCE Ansun BioPharma
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
2. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
3. Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
4. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
5. DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
6. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
7. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
8. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
9. PDL BioPharma Appoints Peter Garcia as Chief Financial Officer
10. Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
11. PDL BioPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2018)... ... October 10, 2018 , ... Boston Biotech Conferences, ... of Wendy Nelson, PhD, as its new CEO. , Dr. Nelson has over ... biotech industry. Most recently, Dr. Nelson was VP of Business Development, Marketing ...
(Date:10/5/2018)... ... October 04, 2018 , ... Shell’s Puget Sound ... grant to purchase a high-tech machine that turns plastic into prosthesis. The Million ... The organization then processes the usable plastic and turns it into 3D printed ...
(Date:10/2/2018)... Calif. (PRWEB) , ... October 02, 2018 , ... ... Undetected or ignored, contamination endangers the reliability and reproducibility of experimental data. Each ... contamination. , In this educational webinar, which is sponsored by Eppendorf , ...
(Date:9/27/2018)... ... 2018 , ... NDA Partners Chairman Carl Peck, MD ... in vitro diagnostic device expert with more than 28 years of experience in ... an Expert Consultant. Her experience includes leadership roles in regulatory strategy, quality systems, ...
Breaking Biology Technology:
(Date:10/11/2018)... ... October 09, 2018 , ... Exalto Bearings UK, ... announces the appointment of Mike Cosgrove as Business Manager. , Cosgrove has over 30 ... the day to day running of the Derby UK facility. , “We are pleased ...
(Date:10/11/2018)... ... October 11, 2018 , ... ODSC Europe 2018 - one of Open ... at the event from September 19-22. , As Europe’s largest applied data science ... tracks and 4 days. Attendees were given key insights and hands-on training ...
(Date:10/11/2018)... ... October 11, 2018 , ... Better lives through a ... for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The Institute, a public-private partnership launched in ... and workforce development in the United States. Biopharmaceuticals are important because they treat ...
Breaking Biology News(10 mins):